/PRNewswire/ nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, today announced the formation of a Medical Advisory Board supporting the commercial.
nanoMesh™ LLC (a subsidiary of Exogenesis Corporation) Announces Secondary Endpoint Achieved in nanoMesh™ Pathogen Inhibiting Protein (PIP) Uptake Studies
nanoMesh™, An Innovative Soft Tissue Repair Implant Possesses A Unique Nanometer-level Surface Texture
News provided by
Share this article
Share this article
BILLERICA, Mass., June 9, 2021 /PRNewswire/ nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the secondary endpoints for the nanoMesh™ Pathogen Inhibiting Protein (PIP) uptake studies. The PIP trials demonstrated controlled uptake
[1] of a series of pathogen inhibiting, tissue integrating enhancing, and scar formation inhibition proteins
[2], including fibronectin
[6] and laminin
[7] by nanoMesh™. nanoMesh™ possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology
Plastic and Reconstructive Surgery Global Open Announces Jeffrey Janis, MD as editor-in-chief
Share Article
Plastic and Reconstructive Surgery Global Open (PRS Global Open), the official open access, peer reviewed, international medical journal of the American Society of Plastic Surgeons, has announced Jeffrey Janis, MD, as editor-in-chief.
Plastic and Reconstructive Surgery Global Open (PRS Global Open) ARLINGTON HEIGHTS, Ill. (PRWEB) January 26, 2021 Plastic and Reconstructive Surgery Global Open (PRS Global Open), the official open access, peer reviewed, international medical journal of the American Society of Plastic Surgeons, has announced Jeffrey Janis, MD, as editor-in-chief.
Since its inception in 2013, the open-access journal quickly established a name for itself. It is indexed in PubMed Central as well as the Web of Science’s Emerging Sources Citation Index and listed in the prestigious Directory o